Business
Media
Conferences
Publications
CME/CE
Resources
Subscribe

|Videos|July 12, 2022

Dr. Catalona on the history of active surveillance in prostate cancer

Author(s)Urology Times staff

William J. Catalona, MD, explains how the approach of active surveillance in prostate cancer emerged alongside the advent of PSA screening.

William J. Catalona, MD, a professor of Urology at Northwestern University Feinberg School of Medicine, provides a history of the use of active surveillance for men with prostate cancer.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

Blur image of medical clinic | Image Credit: © zephyr_p - stock.adobe.com

Individualizing androgen pathway therapy in mCSPC

ByUrology Times staff

August 1st 2026

FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC

ByHannah Clarke

July 31st 2026

Joshua Lang, MD, MS, on integrating molecular biomarkers into clinical practice

ByJoshua Lang, MD, MS

July 31st 2026

Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer

ByHannah Clarke

July 30th 2026

Prostate Cancer Working Group 4: What urologists need to know

ByHannah Clarke

July 28th 2026

Latest CME

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Trending on Urology Times

FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC

Testosterone deficiency: FAQs from the AUA guideline

Individualizing androgen pathway therapy in mCSPC

Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer

Joshua Lang, MD, MS, on integrating molecular biomarkers into clinical practice